India’s government has authorized global tenders for the procurement of 120 patented medicines, including Semaglutide for diabetes, to address shortages and technological barriers in domestic production. The decision aims to improve access to medicines not widely available or produced locally due to patent constraints. This exemption, effective until March 31, 2027, unless revised, follows consultations involving Indian and multinational stakeholders. The move relaxes the public procurement policy’s previous restriction on global tenders for goods valued up to ₹200 crore, part of efforts to support domestic industries under the ‘Atmanirbhar Bharat’ initiative.